INCRELEX- dosis må aldrig fordobles for at erstatte en eller flere forsømte doser. • Patienten skal undgå høj- risiko aktiviteter (såsom voldsom fysisk aktivitet) i 2- 3 timer efter doseringen, især i begyndelsen af INCRELEX- behandlingen, indtil en godt tolereret dosis INCRELEX er fastlagt. • Vejledning i at skifte og rotere injektionssted for hver injektion for at undgå udvikling af lipohypertrofi. • Vejledning i at rapportere en forværret snorken, der kan indikere en øget vækst af mandlerne og/ eller adenoidt væv efter behandlingsstart med INCRELEX. • Rapportering af alvorlig hovedpine, sløret syn og dermed forbundet kvalme og opkastning til lægen. • Rapportering af halthed eller smerter i hoften eller knæene til lægen, så dette kan evalueres.
The dose of INCRELEX should not be doubled to make up for one or more omitted doses. • To avoid engaging in any high-risk activities (such as vigorous physical activity) within 2 - 3 hours after dosing, particularly at the initiation of INCRELEX treatment, until a well-tolerated dose of INCRELEX has been established. • Instructions to change and rotate the site of injection for each injection to avoid the development of lipohypertrophy. • Instructions to report the onset or worsening of snoring that may indicate an increase in growth of tonsils and/ or adenoids following the beginning of treatment with INCRELEX. • To report the onset of severe headache blurred vision and associated nausea and vomiting to their physician. • To report any onset of a limp or complaint of hip or knee pain to their physician so it can be evaluated.